文献速递糖尿病

葡萄糖代谢指标与14年后PET显示的β-淀粉样蛋白和tau负荷之间的关联:弗雷明汉心脏研究结果

Associations Between Glucose Metabolism Measures and Amyloid-β and Tau Load on PET 14 Years Later: Findings From the Framingham Heart Study.
PubMed 文献 · Diabetes Care · 2024-01-01

弗雷明汉心脏研究纳入288名无痴呆参与者(平均年龄43.1岁),分析一次性空腹血糖和胰岛素及HOMA-IR与14年后PET测得的β-淀粉样蛋白和tau负荷的关联。结果显示血糖升高与14年后tau负荷增加相关,与β-淀粉样蛋白无关;该关联仅在APOE ε4非携带者中存在。

要点

  • 血糖升高与14年后tau负荷增加相关,与β-淀粉样蛋白负荷无关。
  • 该关联受APOE ε4携带状态修饰,仅在非携带者(n=225)中观察到。
  • 血浆胰岛素和HOMA-IR经FDR校正后与淀粉样蛋白或tau负荷无关联。

核心结论

  • 研究提示葡萄糖代谢与未来tau负荷增加相关,但与β-淀粉样蛋白负荷无关。

研究设计与样本

  • 研究纳入288名来自弗雷明汉心脏研究的无痴呆参与者(平均年龄43.1岁,标准差10.7,范围20-70岁),具有一次性空腹血浆葡萄糖和胰岛素测定及14年后β-淀粉样蛋白和/或tau的PET测定。
  • 采用线性回归分析检验血浆葡萄糖(连续和分类;升高定义为>100 mg/dL)、血浆胰岛素、HOMA-IR与PET淀粉样蛋白或tau负荷的关联。
  • 当关联显著时,探索年龄、性别和APOE ε4等位基因携带状态是否修饰这些关联。

主要发现

  • 血糖升高与14年后tau负荷增加相关(B [95% CI] = 0.03 [0.01-0.05],P = 0.024,经FDR校正后)。
  • 血糖升高与β-淀粉样蛋白负荷无关联。
  • APOE ε4携带状态修饰该关联(B [95% CI] = -0.08 [-0.12至-0.03],P = 0.001),表明关联仅在APOE ε4非携带者(n = 225)中存在。
  • 血浆胰岛素和HOMA-IR经FDR校正后与14年后β-淀粉样蛋白或tau负荷无关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Type 2 diabetes and glucose metabolism have previously been linked to Alzheimer disease (AD). Yet, findings on the relation of glucose metabolism with amyloid-β and tau pathology later in life remain unclear. RESEARCH DESIGN AND METHODS: We included 288 participants (mean age 43.1 years, SD 10.7, range 20-70 years) without dementia, from the Framingham Heart Study, who had available measures of glucose metabolism (i.e., one-time fasting plasma glucose and insulin) and positron emission tomography (PET) measures of amyloid-β and/or tau 14 years later. We performed linear regression analyses to test associations of plasma glucose (continuously and categorically; elevated defined as >100 mg/dL), plasma insulin, homeostatic model assessment for insulin resistance (HOMA-IR) with amyloid-β or tau load on PET. When significant, we explored whether age, sex, and APOE ε4 allele carriership (AD genetic risk) modified these associations. RESULTS: Our findings indicated that elevated plasma glucose was associated with greater tau load 14 years later (B [95% CI] = 0.03 [0.01-0.05], P = 0.024 after false discovery rate [FDR] correction) but not amyloid-β. APOE ε4 carriership modified this association (B [95% CI] = -0.08 [-0.12 to -0.03], P = 0.001), indicating that the association was only present in APOE ε4 noncarriers (n = 225). Plasma insulin and HOMA-IR were not associated with amyloid-β or tau load 14 years later after FDR correction. CONCLUSIONS: Our findings suggest that glucose metabolism is associated with increased future tau but not amyloid-β load. This provides relevant knowledge for prevention strategies and prognostics to improve health care.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. van Gils V, Tao Q, Ang TFA, et al. Associations Between Glucose Metabolism Measures and Amyloid-β and Tau Load on PET 14 Years Later: Findings From the Framingham Heart Study. Diabetes Care. 2024. PMID: 39078159. doi:10.2337/dc24-0162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。